Obesity Market Potential Is Huge, But Access To Drugs An Increasing Challenge

Novo’s SELECT Readout For Wegovy May Answer Payer Questions

Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.

healthy nutritional food eating lifestyle to prevent heart disease and diabetes — Showing that obesity drugs can improve diabetes and heart health may be key to reimbursement • Source: Shutterstock

While the GLP-1 agonists have been hailed for their double-digit percentage weight reductions in clinical trials presented at the recent American Diabetes Association (ADA) annual meeting, data on how significant weight loss can improve or prevent cardiometabolic comorbidities may be what is needed to improve payer coverage. Given the numbers of people eligible for treatment and the costs of new medicines, there are growing concerns that many who could greatly benefit from obesity drugs will not be able to access them.

Accessibility already is a problem for Novo Nordisk A/S’s Wegovy (semaglutide), which the company has struggled to manufacture at...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

Roche Keen To Cut Out The Middle Men On US Pricing

24 Jul 2025

• By Kevin Grogan

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

18 Jul 2025

• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

17 Jul 2025

• By Alaric DeArment

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

18 Jun 2025

• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions

25 Jul 2025

• By Alaric DeArment

Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.